NewAmsterdam Pharma Subsidiary Secures Supply Agreement with Menarini for Obicetrapib Products
NewAmsterdam Pharma Company NV recently announced a significant development with its subsidiary, NewAmsterdam Pharma B.V., entering into a Supply Agreement with A. Menarini International Licensing S.A. This agreement, following the License Agreement from June 2022, designates the subsidiary as the exclusive supplier of obicetrapib monotherapy and a fixed-dose combination of obicetrapib and ezetimibe to Menarini. The supply will be based on volume forecasts provided by Menarini, with pricing determined by a specified mark-up on the cost of goods sold. The agreement outlines a future transfer of drug manufacturing to Menarini or a designated third-party manufacturer, with a non-exclusive license granted for the manufacturing process. The Supply Agreement is set to last as long as the License Agreement continues, with provisions for termination under certain conditions. This strategic partnership marks a pivotal step in the expansion of NewAmsterdam Pharma's market presence.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NewAmsterdam Pharma Company NV published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000950170-25-109387), on August 15, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.